{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:47:36Z","timestamp":1789026456198,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116729","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:05:18Z","timestamp":1775783118000},"page":"116729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279,\u00a0an anti-PD-1 monoclonal antibody in patients with advanced solid tumours"],"prefix":"10.1016","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-2942","authenticated-orcid":false,"given":"Marie","family":"Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Kotecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-2529","authenticated-orcid":false,"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5505-0564","authenticated-orcid":false,"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Raimbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-3544","authenticated-orcid":false,"given":"Mariana","family":"Brandao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-5932","authenticated-orcid":false,"given":"Iphig\u00e9nie","family":"Korakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut de la motte","family":"Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Comis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Imadalou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-2397","authenticated-orcid":false,"given":"Constant","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Teppaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Seit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Thepenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-0449","authenticated-orcid":false,"given":"Vanessa","family":"Gauttier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myl\u00e8ne","family":"Derame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Morello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-1688","authenticated-orcid":false,"given":"Philippe Alexandre","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116729_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"10.1016\/j.ejca.2026.116729_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.ejca.2026.116729_bib3","article-title":"Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.ejca.2026.116729_bib4","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian optimal interval design: a simple and well-performing design for phase i oncology trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2026.116729_bib5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1177\/0962280215594494","article-title":"Bayesian optimal interval design for dose finding in drug-combination trials","volume":"26","author":"Lin","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.116729_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116729_bib7","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9948","key":"10.1016\/j.ejca.2026.116729_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2026.116729_bib9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116729_bib10","doi-asserted-by":"crossref","unstructured":"Yan T., Yu L., Jingyi, Shangguan D., Lei W. et al. Advances in pharmacokinetics and pharmacodynamics of PD-1\/ PD-L1 inhibitors. 2023, 109638.","DOI":"10.1016\/j.intimp.2022.109638"},{"key":"10.1016\/j.ejca.2026.116729_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","article-title":"Optimal biological dose: a systematic review in cancer phase I clinical trials","volume":"21","author":"Fraisse","year":"2021","journal-title":"BMC Cancer"},{"issue":"27","key":"10.1016\/j.ejca.2026.116729_bib12","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2008.16.6462","article-title":"Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10 epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer","volume":"26","author":"Barve","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116729_bib13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:23:50Z","timestamp":1779294230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"alternative-id":["S0959804926005095"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116729","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279,\u00a0an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116729"}}